Source comparison
Melanotan-1 for Tanning Research Evidence Comparison
Mechanism DNA damage triggers p53-mediated melanogenesis as a stress response Direct MC1R agonism stimulates melanin synthesis without DNA insult Afamelanotide bypasses the damage-repair cycle entirely. Melanogenesis occurs as a pharmacological effect, not a w
This comparison does not assign a generated winner or score.
- Mechanism
- DNA damage triggers p53-mediated melanogenesis as a stress response
- Direct MC1R agonism stimulates melanin synthesis without DNA insult
- Afamelanotide bypasses the damage-repair cycle entirely. Melanogenesis occurs as a pharmacological effect, not a wound-healing response
- Eumelanin:Pheomelanin Ratio
- Variable. Fair skin produces more pheomelanin (red pigment with poor UV protection)
- Consistently increases eumelanin production across all skin types
- Higher eumelanin ratio confers genuine photoprotection; pheomelanin may increase oxidative stress under UV exposure
- Cyclobutane Pyrimidine Dimer Formation
- CPDs form immediately upon UVB exposure. Primary initiator of melanoma mutations
- 52% reduction in CPD formation when skin is pre-pigmented via afamelanotide
- Pre-treatment creates photoprotective melanin shield before UV exposure, preventing DNA lesions rather than repairing them afterward
- Duration of Effect
- Fades within 2–4 weeks as melanocytes return to baseline and stratum corneum sheds
- Sustained pigmentation for 60–90 days post-administration due to increased melanosome stability
- Longer duration reduces re-administration frequency. Relevant for protocol design in photoprotection research
- FDA Regulatory Status
- No approval required (endogenous process)
- FDA-approved for erythropoietic protoporphyria (Scenesse, 2019)
- Regulatory approval based on Phase 3 randomised controlled trial data. Highest tier of clinical evidence